Parkinson’s disease managing reversible neurodegeneration

QR Code

Parkinson’s disease managing reversible neurodegeneration

Marty Hinz,1 Alvin Stein,2 Ted Cole,3 Beth McDougall,4 Mark Westaway5 1Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, 2Stein Orthopedic Associates, Plantation, FL, 3Cole Center for Healing, Cincinnati, OH, 4CLEARCenter of Health, Mill Valley, CA, USA; 5Four Pillars Health, Brendale...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Hinz M, Stein A, Cole T, McDougall B, Westaway M
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2016
Sujets:	Parkinson’s disease L-dopa carbidopa B6 neurodegeneration Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/864f8d4ee4da431d8d86580a3e5f76d3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Parkinson’s Disease Managing Reversible Neurodegeneration [Retraction]
par: Hinz M, et autres
Publié: (2020)

Parkinson’s Disease Managing Reversible Neurodegeneration [Expression of Concern]
par: Hinz M, et autres
Publié: (2020)

Parkinson's disease managing reversible neurodegeneration [Corrigendum]
par: Hinz M, et autres
Publié: (2016)

Parkinson’s Disease-Associated Melanin Steal [Retraction]
par: Hinz M, et autres
Publié: (2021)

Parkinson’s Disease-Associated Melanin Steal [Expression of Concern]
par: Hinz M, et autres
Publié: (2020)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden
par: Modugno N, et autres
Publié: (2020)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
par: Bigman DY, et autres
Publié: (2018)

Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
par: Szász JA, et autres
Publié: (2019)

Parkinson’s disease-associated melanin steal
par: Hinz M, et autres
Publié: (2014)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
par: Hu S, et autres
Publié: (2020)

Comparación farmacocinética de Sinemetây Grifoparkinâ (levodopa/carbidopa 250/25 mg) en pacientes con enfermedad de Parkinson avanzada: un estudio con dosis única
par: Chaná C,Pedro, et autres
Publié: (2003)

The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Retraction]
par: Hinz M, et autres
Publié: (2021)

The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Expression of Concern]
par: Hinz M, et autres
Publié: (2020)

Neuropsychiatric symptoms in untreated Parkinson’s disease
par: Szatmari S, et autres
Publié: (2017)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
par: Hauser RA, et autres
Publié: (2018)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
par: Constantin VA, et autres
Publié: (2020)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
par: Combs BL, et autres
Publié: (2017)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
par: Schettino C, et autres
Publié: (2016)

Sleep apnea leading to Parkinson’s disease – an important association
par: Shafqat MN, et autres
Publié: (2017)

Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson’s disease
par: Alicia Flores-Cuadrado, et autres
Publié: (2021)

Current Perspectives on the Assessment and Management of Gait Disorders in Parkinson’s Disease
par: Smith MD, et autres
Publié: (2021)

Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis
par: Zhang H, et autres
Publié: (2019)

Cytological and cytometric analysis of oral mucosa in patients with Alzheimer’s and Parkinson’s disease
par: Kose Ozlece H, et autres
Publié: (2018)

Neuroprotective effect and mechanism of baicalin on Parkinson’s disease model induced by 6-OHDA
par: Tu L, et autres
Publié: (2020)

Effects of Carbidopa Premedication on <sup>18</sup>F-FDOPA PET Imaging of Glioma: A Multiparametric Analysis
par: Marie Bros, et autres
Publié: (2021)

Lack of Association Between PLA2G6 Genetic Variation and Parkinson’s Disease: A Systematic Review
par: Liu H, et autres
Publié: (2020)

Psychosis in parkinsonism: an unorthodox approach
par: Onofrj M, et autres
Publié: (2017)

Treatment of Attention Deficit Hyperactivity Disorder with Monoamine Amino Acid Precursors and Organic Cation Transporter Assay Interpretation [Expression of Concern]
par: Hinz M, et autres
Publié: (2020)

Treatment of Attention Deficit Hyperactivity Disorder with Monoamine Amino Acid Precursors and Organic Cation Transporter Assay Interpretation [Retraction]
par: Hinz M, et autres
Publié: (2020)

Altered emotional recognition and expression in patients with Parkinson’s disease
par: Jin Y, et autres
Publié: (2017)

Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients
par: Szász JA, et autres
Publié: (2019)

Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds
par: Jennifer A. Macdonald, et autres
Publié: (2021)

A door-to-door survey to estimate the prevalence of Parkinsonism in Pakistan
par: Khan S, et autres
Publié: (2016)

Glia maturation factor-β: a potential therapeutic target in neurodegeneration and neuroinflammation
par: Fan J, et autres
Publié: (2018)

The role of deep brain stimulation in Parkinson’s disease: an overview and update on new developments
par: Fang JY, et autres
Publié: (2017)

Cognitive Influences in Parkinson's Disease Patients and Their Caregivers: Perspectives From an Australian Cohort
par: Michal Lubomski, et autres
Publié: (2021)

High frequency of psychosis in late-stage Parkinsońs disease
par: Inês Chendo, et autres
Publié: (2021)

Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
par: Murakami H, et autres
Publié: (2017)

Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration
par: G. Carola, et autres
Publié: (2021)

Affective theory of mind in Parkinson’s disease: the effect of cognitive performance
par: Romosan AM, et autres
Publié: (2019)